Peptide Therapeutic Candidate for Treating Conditions Caused by gamma-Herpesvirsus (RFT-456)
Epstein-Barr, Kaposi’s Sarcoma, and other gamma-herpesviruses (γHV) infect over 95% of humans. The viruses are normally kept in check by the immune system, but (especially in stressed, or immunocompromised patients), the viruses may lead to malignant tumors, Epstein-Barr syndrome, infectious mononucleosis, and other diseases. There is no treatment for any of these diseases. Instead, the best current option is to ‘manage’ the condition. Potential therapeutic treatment is hindered because humans have proteins that are very similar to the key herpesvirus proteins. A viable treatment must disrupt the viral proteins, while leaving the human versions unimpaired.
- Potential to treat diseases that are currently untreatable. As noted, diseases caused by γHVs are managed, not treated or cured.
- Minimal side effects due to the specific binding of viral Bcl-2, not human Bcl-2
- Therapeutic to treat diseases caused by γHV
- Research to understand the role of viral Bcl-2 and γHV in causing diseases.
The licensable technology is a potential therapeutic peptide that specifically binds to γHV Bcl-2 proteins, and has been shown to dramatically reduce the activity of viral Bcl-2, but not human Bcl-2, in transfected mammalian cells.
This technology is patent pending with worldwide patent options available and is available for licensing/partnering opportunities.
Henry Nowak, Technology Manager
Inquire about this technology >